A new long-lasting prophylactic HIV drug, the foundation for which was developed at the University of Utah, has been named the Breakthrough of the Year by the scientific journal Science. Initial foundational research for the drug lenacapavir, developed by Gilead Sciences, was done by Wesley Sundquist, the Samuels Professor and chair of biochemistry at the UofU.
Lenacapavir provides protection from the HIV virus for six months instead of one day and has performed extremely well in clinical trials.
Sundquist’s research focuses on understanding how the HIV virus is built on a molecular level and how it interacts with Please log in to see the rest of this story.
